ReviewInfection and drug resistance2015
Efinaconazole in the treatment of onychomycosis.
Review in Infection and drug resistance, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- From Chemistry to Clinic: Amorphous Solid-State Modification Strategies for Oral Azole Antifungals.ACS omega · 2026Review
- Rising antifungal resistance inFrontiers in microbiology · 2026Review
- Article
- Antifungal Agents' Trends of Utilization, Spending, and Prices in the US Medicaid Programs: 2009-2023.Antibiotics (Basel, Switzerland) · 2025Article
- Impact of new antifungal medications on onychomycosis prescriptions and costs in Japan: A nationwide claims database study.The Journal of dermatology · 2024Article
- Antifungal Selection for the Treatment of Onychomycosis: Patient Considerations and Outcomes.Infection and drug resistance · 2024Review
- Evaluation of the efficacy of novel topical antifungal agents against dermatophytes in North India: A prospective study.Current medical mycology · 2024Article
- Formulation-by-Design of Efinaconazole Spanlastic Nanovesicles for Transungual Delivery Using Statistical Risk Management and Multivariate Analytical Techniques.Pharmaceutics · 2022Article
- Preparation andDrug delivery · 2019Article
- ONYCHOMYCOSIS: A Review of New and Emerging Topical and Device-based Treatments.The Journal of clinical and aesthetic dermatology · 2019Review
- LowAntimicrobial agents and chemotherapy · 2018Article
- An invertebrate infection model for evaluating anti-fungal agents against dermatophytosis.Scientific reports · 2017Article
- An Assessment of In Vitro Antifungal Activities of Efinaconazole and Itraconazole against Common Non-Dermatophyte Fungi Causing Onychomycosis.Journal of fungi (Basel, Switzerland) · 2017Article
- Successful Treatment of Paecilomyces lilacinus Onychomycosis with Efinaconazole and Tavaborole.Skin appendage disorders · 2016Article
- Article
- Newer Topical Treatments in Skin and Nail Dermatophyte Infections.Indian dermatology online journalReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Efinaconazole 10% topical solution is a new triazole recently approved for the treatment of onychomycosis. It inhibits fungal lanosterol 14α-demethylase in the ergosterol biosynthesis pathway, has potent antifungal activity against dermatophytes, as well as activity against Candida spp. and non-dermatophyte molds, and showed promising results in clinical trials. This review summarizes the mechanism of action, in vitro and in vivo data, clinical trials, safety, and quality-of-life data of efinaconazole as it applies to the treatment of onychomycosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.